Follow the Pundits
Tag: Funanc1al Edge
Baker Bros Are Bullish — Can Kodiak Kill the Bears?
When the sharpest biotech investors on the planet deploy $60 million, it’s worth paying attention. Kodiak Sciences is a high-risk, high-reward retinal biotech with late-stage trials, real institutional backing, and binary outcomes ahead. Fun, factual, and unapologetically speculative.
Kenvue Director Jeff Smith of Starboard Value Buys Shares of KVUE; He Must Love Kimberly-Clark. Should You?
A $111 million insider buy. Nearly 100% institutional ownership. A blockbuster merger with Kimberly-Clark. Kenvue suddenly looks boring… in a very interesting way.
Biotech Investor Extraordinaire Baker Bros Adds to Its Massive Stake in Kymera. Should You Buy In?
Baker Bros — the Warren Buffetts of biotech — just super-sized their Kymera (KYMR) position. With Fast Track designation, jaw-dropping STAT6 trial results, and a pioneering protein-degradation platform, is KYMR becoming the next biotech legend?
Could MGM Suddenly Stand for “My Great Money-Maker?”
Barry Diller is doubling down, insiders are buying, and MGM’s digital arm is gaining traction. Is the casino giant quietly becoming a global money machine again?
New CEO and Activist Corvex’s Keith Meister Buy Vestis; Expect Profits or Casual Tees?
A new CEO with UPS DNA, millions in insider buys, and activist hedge fund Corvex circling… Vestis stock checks many contrarian boxes. But high leverage and a slow turnaround mean this is not for the faint of heart. 👕📈
Paulson & Co Keeps Adding to His Bausch Health Stake: Should Investors See Eye to Eye With Him?
Billionaire John Paulson now owns nearly 19% of Bausch Health — and he keeps buying. With improving earnings, low valuation, and high risk, BHC may be a speculative value play worth watching.
Biotech Venture Capital Firm Casdin Keeps Buying Standard BioTools Shares — Time To Invest, Or Time To Label This “Highly Experimental”?
Casdin Capital just scooped up over a million shares of Standard BioTools — again. With strong tech, big cash coming from Illumina, and a major restructuring underway, is this small-cap biotech tools maker a deep-value setup or just another “high-risk, high-lab-cost” gamble? Here’s what’s really going on.
Key Director and Bessemer Partner Buys Over $5M of ACV Auctions: Time to Bid, or Just Mor-Bid Curiosity?
A major insider just snapped up 912,408 shares of ACV Auctions—over $5.1 million worth. Institutions are stuffed with shares, revenue is growing nearly 20%, and profits are inching closer. Should investors bid… or back away slowly?
Carl Icahn Buys More Monro: Time to Load Up on MNRO—or Tap the Brakes?
Carl Icahn just topped off his tank with more Monro stock. The auto repair chain is shifting gears with a turnaround plan—but will it drive profits or hit a pothole? 🚗💡
Amazon Is ValueAct Holdings’ Top Holding. Should You Buy?
ValueAct didn’t nibble—Amazon is its top holding. Under the hood: AWS growth, retail media margins, and AI making robots, delivery, and dev tools smarter. Not cheap—but quality compounding can justify the tag. Read our Quick Take, risks box, and how to buy dips with a cool head.